NL-OMON42537CompletedPhase 3
A multi-center, Randomized, double-blind, placebo-controlled study to Evaluate the Safety and efficacy of a single oral dose of vanoxerine for The conversion Of subjects with REcent onset atrial fibrillation or flutter to normal Sinus Rhythm - RESTORE SR
aguna Pharmaceuticals, Inc0 sites16 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 16
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Onset of Atrial fibrillation/Atrial Flutter within the 7 calendar days preceding randomisation, based on symptoms. AF/AFL documented by ECG during the screening period and immediately prior to study drug administration. (see protocol page 30)
Exclusion Criteria
- •See protocol page 30 and 31
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A sleep laboratory study to investigate the safety and efficacy of the rotigotine skin patch in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysisRestless Legs Syndrome in patients with End Stage Renal Disease (ESRD)MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-003486-15-DECB BIOSCIENCES GmbH48
Active, not recruiting
Not Applicable
Study designed to demonstrate the efficacy and safety of Certolizumab pegol in combination with Methotrexate in the treatment of subjects suffering from early, progressive active rheumatoid arthritis.Early active rheumatoid arthritisMedDRA version: 17.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859EUCTR2011-001729-25-DECB Pharma SA800
Active, not recruiting
Not Applicable
Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failureType 2 Diabetes. Heart failure (NYHA class I-III).MedDRA version: 13.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: LLTClassification code 10064081Term: Heart failure NYHA class IIISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064079Term: Heart failure NYHA class ISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064080Term: Heart failure NYHA class IISystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-005012-41-LVovartis Pharma Services AG490
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotideIrritable Bowel SyndromMedDRA version: 9.1Level: PTClassification code 10023003Term: Irritable bowel syndromeEUCTR2007-004994-25-SEovartis Pharma Services AG46
Active, not recruiting
Phase 1
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAIEUCTR2006-005520-16-SKF. Hoffmann-La Roche Ltd1,060